NGNatalia Genere

Natalia Genere

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalia Genere has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Irina Bancos

    Division of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA

    4 shared publications
  • Elizabeth J Atkinson

    Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic , Rochester, MN 55905

    2 shared publications
  • Sara J Achenbach

    Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic , Rochester, MN 55905

    2 shared publications
  • Shobana Athimulam

    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota

    2 shared publications
  • Adina F Turcu

    Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, MI 48109 , United States

    1 shared publication
  • Alexandra N Bancos

    Division of Endocrinology and Metabolism, Department of Medicine, Mayo Clinic , Rochester, MN 55905

    1 shared publication

Latest Publications

  • Open Access

    Adrenal crises and quality of life after bilateral adrenalectomy versus primary autoimmune adrenal insufficiency

    by Alexandra N Bancos, Raul Gregg-Garcia, Natalia Genere, Sanan Mahrokhian, Sara J Achenbach, Elizabeth J Atkinson, Anand Vaidya, Irina Bancos

    Context: Bilateral adrenalectomy (BLA) and autoimmune adrenal insufficiency (AAI) are two major causes of primary adrenal insufficiency (PAI). Comparative data between etiologies are limited. Objective: To compare management, quality of life (QoL), and frequency of adrenal crises between participants post-BLA versus AAI. Methods: We conducted a dual-center, cross-sectional study of adults with AAI or BLA, 2018-2025. All participants completed questionnaires on management, adrenal crises, and the Addison disease-specific QoL questionnaire (AddiQoL). Results: Of 343 participants, 203 had AAI (median age 54 years, 72% women) and 139 had BLA (median age 57 years, 76% women). AddiQoL scores were similar between participants with AAI and BLA (median 84 vs 83, P=0.947), but better in participants post-BLA for pheochromocytoma vs hypercortisolism (median 88 vs 81, P=0.031). Participants with AAI reported a higher number of adrenal crises within the last year than those post-BLA (25% vs 13%, P=0.022). In multivariable analyses of age, sex, glucocorticoid dose and type, PAI type, AddiQoL score, and autoimmune comorbidities, only PAI type was associated with higher number of reported adrenal crisis within the last year (AAI vs BLA: Odds Ratios of 2.1-2.2, P<0.05 for all models). Conclusion: QoL was comparable between participants with AAI and BLA, though patients post-BLA for pheochromocytoma reported better QoL than patients post-BLA for hypercortisolism. Adrenal crises were more common in participants with AAI than those post-BLA, a finding that was not explained by patients’ glucocorticoid management, underscoring the need for tailored crisis prevention strategies.


  • Open Access

    Characterization of adrenal masses in young adults at a tertiary care academic medical center

    by Sarah Jacob, Malak Itani, Mark J Hoegger, Daniel R Ludwig, T K Pandian, Claudia Villatoro Santos, L Michael Brunt, Irina Bancos, Natalia Genere

    Context: Evidence on the etiology and function of adrenal masses in younger adults is scarce. Objective: This work aimed to characterize the clinical, imaging, and biochemical presentation of adrenal masses in 18- to 40-year-olds. Methods: A retrospective cohort study was conducted January 2016 to December 2021 at a tertiary academic medical center. Participants included young adults (age 18-40 years) with adrenal masses identified through radiologic registry. Exclusion criteria included preexisting adrenal masses before 2016, hyperplasia, or masses smaller than 1 cm. Outcomes included adrenal mass diagnosis, as determined by reference standard of histopathology, radiologic surveillance, and biochemical evaluation. Results: A total of 255 patients (women 142 [56%]; White 156 [61%]; median age 35 years [interquartile range 30-39 years]) were included. Comorbidities included genetic predisposition syndromes (16, 6.3%), preexisting malignancy (70, 27%), obesity (100, 48%), hypertension (89, 35%), and diabetes (25, 10%). The majority of adrenal masses were incidentally found (184, 72%) and median size was 1.9 cm (IQR 1.4-2.7 cm) on detection. Among adrenal masses in young adults, prevalence of malignancy and pheochromocytoma was 16% and 4%, respectively; among adrenal incidentalomas, 5% were malignant. Factors associated with malignancy or pheochromocytoma in multivariable analysis included nonincidental mechanism of discovery (odds ratio [OR] 15.5; 95% CI, 7.2-35.7; P < .001), and larger size (OR 1.5; 95% CI, 1.2-2.0; P < .001). Hormonal evaluation was performed in only 57 (22%) patients and was positive for hormone hypersecretion in 16 (28%) of tested individuals. Conclusion: We demonstrated a high prevalence of malignancy and pheochromocytoma in our cohort of young adults with adrenal masses. Completion of appropriate hormonal work-up was infrequent, potentially missing patients with functioning adrenal adenomas.

  • High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment

    by Prerna Dogra, Lana Šambula, Jasmine Saini, Karthik Thangamuthu, Shobana Athimulam, Danae A Delivanis, Dimitra A Baikousi, Rohit Nathani, Catherine D Zhang, Natalia Genere, et al.

    Objective: Frailty, characterized by multi-system decline, increases vulnerability to adverse health outcomes and can be measured using Frailty Index (FI). We aimed to assess the prevalence of frailty in patients with adrenal disorders (based on hormonal sub-type) and examine association between FI and performance-based measures of physical function. Design: Multi-centre, cross-sectional study (March 2019-August 2022). Methods: Adult patients with adrenal disorders (non-functioning adrenal adenomas [NFA], mild autonomous cortisol secretion [MACS], Cushing syndrome [CS], primary aldosteronism [PA]) and referent subjects without adrenal disorders completed a questionnaire encompassing 47 health variables (comorbidities, symptoms, daily living activities). FI was calculated as the average score of all variables and frailty defined as FI ≥ 0.25. Physical function was assessed with hand grip, timed up-and-go test, chair rising test, 6-minute walk test, and gait speed. Results: Compared to referent subjects (n = 89), patients with adrenal disorders (n = 520) showed increased age, sex, and body mass index-adjusted prevalence of frailty (CS [odds ratio—OR 19.2, 95% confidence interval—CI 6.7-70], MACS [OR 12.5, 95% CI 4.8-42.9], PA [OR 8.4, 95% CI 2.9-30.4], NFA [OR 4.5, 95% CI 1.7-15.9]). Prevalence of frailty was similar to referent subjects when post-dexamethasone cortisol was <28 nmol/L and was higher when post-dexamethasone cortisol was 28-50 nmol/L (OR 4.6, 95% CI 1.7-16.5). FI correlated with all measures of physical function (P < .001). Conclusions: Whilst frailty prevalence was highest in patients with adrenocortical hormone excess, even patients with NFA demonstrated an increased prevalence compared to the referent population. Future longitudinal studies are needed to evaluate the impact of various management strategies on frailty.


  • Incidence of Clinically Relevant Thyroid Cancers Remains Stable for Almost a Century

    by Natalia Genere, Omar M. El Kawkgi, Rachel E. Giblon, Salvatore Vaccarella, John C. Morris, Ian D. Hay, Juan P. Brito


  • Open Access

    Interpretation of Abnormal Dexamethasone Suppression Test is Enhanced With Use of Synchronous Free Cortisol Assessment

    by Natalia Genere, Ravinder Jeet Kaur, Shobana Athimulam, Melinda A Thomas, Todd Nippoldt, Molly Van Norman, Ravinder Singh, Stefan Grebe, Irina Bancos

    Context Interpretation of dexamethasone suppression test (DST) may be influenced by dexamethasone absorption and metabolism and by the altered cortisol binding. Objective We aimed to determine the normal ranges of free cortisol during DST in participants without adrenal disorders and to identify the population of patients where post-DST free cortisol measurements add value to the diagnostic workup. Design and Setting Cross-sectional study conducted in a tertiary medical center. Participants Adult volunteers without adrenal disorders (n = 168; 47 women on oral contraceptive therapy [OCP], 66 women not on OCP, 55 men) and patients undergoing evaluation for hypercortisolism (n = 196; 16 women on OCP). Measurements Post-DST dexamethasone and free cortisol (mass spectrometry) and total cortisol (immunoassay). Main Outcome Measures Reference range for post-DST free cortisol, diagnostic accuracy of post-DST total cortisol. Results Adequate dexamethasone concentrations (≥0.1 mcg/dL) were seen in 97.6% volunteers and 96.3% patients. Only 25.5% of women volunteers on OCP had abnormal post-DST total cortisol (>1.8 mcg/dL). In volunteers, the upper post-DST free cortisol range was 48 ng/dL in men and women not on OCP, and 79 ng/dL in women on OCP. When compared with post-DST free cortisol, diagnostic accuracy of post-DST total cortisol was 87.3% (95% CI, 81.7-91.7); all false-positive results occurred in patients with post-DST cortisol between 1.8 and 5 mcg/dL. OCP use was the only factor associated with false-positive results (21.1% vs 4.9%, P = 0.02). Conclusions Post-DST free cortisol measurements are valuable in patients with optimal dexamethasone concentrations and post-DST total cortisol between 1.8 and 5 mcg/dL.